These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 39279643)

  • 21. Short-chain fatty acids exert opposite effects on the expression and function of p-glycoprotein and breast cancer resistance protein in rat intestine.
    Xie QS; Zhang JX; Liu M; Liu PH; Wang ZJ; Zhu L; Jiang L; Jin MM; Liu XN; Liu L; Liu XD
    Acta Pharmacol Sin; 2021 Mar; 42(3):470-481. PubMed ID: 32555444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional intestinal monolayers from organoids derived from human iPS cells for drug discovery research.
    Inui T; Uraya Y; Yokota J; Yamashita T; Kawai K; Okada K; Ueyama-Toba Y; Mizuguchi H
    Stem Cell Res Ther; 2024 Feb; 15(1):57. PubMed ID: 38424603
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prandial state and biological sex modulate clinically relevant efflux transporters to different extents in Wistar and Sprague Dawley rats.
    Gavins FKH; Dou L; Qin Y; Madla CM; Murdan S; Basit AW; Mai Y; Orlu M
    Biomed Pharmacother; 2023 Apr; 160():114329. PubMed ID: 36731343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical interaction of anti-HCV telaprevir with the ABC transporters P-glycoprotein and breast cancer resistance protein.
    Fujita Y; Noguchi K; Suzuki T; Katayama K; Sugimoto Y
    BMC Res Notes; 2013 Nov; 6():445. PubMed ID: 24196382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intestinal organoids as an in vitro platform to characterize disposition, metabolism, and safety profile of small molecules.
    Kourula S; Derksen M; Jardi F; Jonkers S; van Heerden M; Verboven P; Theuns V; Van Asten S; Huybrechts T; Kunze A; Frazer-Mendelewska E; Lai KW; Overmeer R; Roos JL; Vries RGJ; Boj SF; Monshouwer M; Pourfarzad F; Snoeys J
    Eur J Pharm Sci; 2023 Sep; 188():106481. PubMed ID: 37244450
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of fedratinib on the pharmacokinetics of transporter probe substrates using a cocktail approach.
    Ogasawara K; Wood-Horrall RN; Thomas M; Thomas M; Liu L; Liu M; Xue Y; Surapaneni S; Carayannopoulos LN; Zhou S; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):941-952. PubMed ID: 34477937
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
    Shimizu R; Matsuzaki T; Oka R; Sonoyama T; Fukuhara T; Kuwata A; Matsuo Y; Kubota R
    J Clin Pharmacol; 2023 Aug; 63(8):918-927. PubMed ID: 37043676
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of quantifying ABC transporters by mass spectrometry and impact on in vitro-to-in vivo prediction of transporter-mediated drug-drug interactions of rivaroxaban.
    Jacqueroux E; Hodin S; Saib S; He Z; Bin V; Delézay O; Delavenne X
    Eur J Pharm Biopharm; 2020 Mar; 148():27-37. PubMed ID: 31945490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Letter to the Editor, Physiologically based pharmacokinetic predictions of intestinal BCRP-mediated effect of telmisartan on the pharmacokinetics of rosuvastatin in humans.
    de Kanter R; Kohl C
    Biopharm Drug Dispos; 2017 Oct; 38(7):443-444. PubMed ID: 28656708
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of the Human Intestinal Drug Transport with Ussing Chamber System Incorporating Freshly Isolated Human Jejunum.
    Michiba K; Maeda K; Kurimori K; Enomoto T; Shimomura O; Takeuchi T; Nishiyama H; Oda T; Kusuhara H
    Drug Metab Dispos; 2021 Jan; 49(1):84-93. PubMed ID: 33087448
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In-depth analysis of the relationship between bovine intestinal organoids and enteroids based on morphology and transcriptome.
    Zhang J; Li J; Yan P; He L; Zhang X; Wang X; Shi Y; Deng L; Zhang Z; Zhao B
    J Tissue Eng Regen Med; 2022 Nov; 16(11):1032-1046. PubMed ID: 36128613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal ischemia-reperfusion increases efflux for uric acid via paracellular route in the intestine, but decreases that via transcellular route mediated by BCRP.
    Ogura J; Kuwayama K; Takaya A; Terada Y; Tsujimoto T; Koizumi T; Maruyama H; Fujikawa A; Takahashi N; Kobayashi M; Itagaki S; Hirano T; Yamaguchi H; Iseki K
    J Pharm Pharm Sci; 2012; 15(2):295-304. PubMed ID: 22579008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABC transporter (P-gp/ABCB1, MRP1/ABCC1, BCRP/ABCG2) expression in the developing human CNS.
    Daood M; Tsai C; Ahdab-Barmada M; Watchko JF
    Neuropediatrics; 2008 Aug; 39(4):211-8. PubMed ID: 19165709
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible inhibition of efflux transporters by hydrogel microdevices.
    Levy ES; Samy KE; Lamson NG; Whitehead KA; Kroetz DL; Desai TA
    Eur J Pharm Biopharm; 2019 Dec; 145():76-84. PubMed ID: 31639417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass.
    Bruyère A; Declèves X; Bouzom F; Ball K; Marques C; Treton X; Pocard M; Valleur P; Bouhnik Y; Panis Y; Scherrmann JM; Mouly S
    Mol Pharm; 2010 Oct; 7(5):1596-607. PubMed ID: 20604570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Transporter Polymorphisms as a Factor in a BCRP Drug Interaction Study With Lanabecestat.
    Willis BA; Andersen SW; Ayan-Oshodi M; James DE; Liffick E; Hillgren K; Guo Y; Monk SA
    J Clin Pharmacol; 2020 Jan; 60(1):107-116. PubMed ID: 31378968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantitative prediction of breast cancer resistant protein mediated drug-drug interactions using physiologically-based pharmacokinetic modeling.
    Costales C; Lin J; Kimoto E; Yamazaki S; Gosset JR; Rodrigues AD; Lazzaro S; West MA; West M; Varma MVS
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1018-1031. PubMed ID: 34164937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ontogeny of Small Intestinal Drug Transporters and Metabolizing Enzymes Based on Targeted Quantitative Proteomics.
    Kiss M; Mbasu R; Nicolaï J; Barnouin K; Kotian A; Mooij MG; Kist N; Wijnen RMH; Ungell AL; Cutler P; Russel FGM; de Wildt SN
    Drug Metab Dispos; 2021 Dec; 49(12):1038-1046. PubMed ID: 34548392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Infant and adult human intestinal enteroids are morphologically and functionally distinct.
    Adeniyi-Ipadeola GO; Hankins JD; Kambal A; Zeng X-L; Patil K; Poplaski V; Bomidi C; Nguyen-Phuc H; Grimm SL; Coarfa C; Stossi F; Crawford SE; Blutt SE; Speer AL; Estes MK; Ramani S
    mBio; 2024 Aug; 15(8):e0131624. PubMed ID: 38953637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.